title: The link between non-ergot-derived dopamine agonists and heart failure: how strong is it?
abstract: Dopamine agonists are commonly used as initial monotherapy and adjunct treatment for Parkinson's disease. However, the Food and Drug Administration recently linked pramipexole use with an increased risk of heart failure (HF). Several case-control studies demonstrate a possible increased risk of the development of HF in patients taking non-ergot-derived dopamine agonists compared with patients not taking dopamine agonists. In patients taking non-ergot-derived dopamine agonists, the studies associated the risk of increased HF with pramipexole. These studies did not find a possible increased risk with ropinirole, but to date no randomized, controlled trials have been conducted to directly compare ropinirole with pramipexole and the risk of HF. The mechanism by which HF occurs is unknown, but the development of edema after dopamine agonist use could increase the risk of HF. If patients with a history of cardiovascular disease or edema are prescribed pramipexole, additional monitoring for HF signs and symptoms is recommended.
authors.affiliation: Northeast Methodist Hospital, Live Oak, Texas, USA.
authors.forename: Katrina
authors.initials: K
authors.lastname: Lockett
authors.forename: Danielle
authors.initials: D
authors.lastname: DeBacker
authors.forename: Kimberly A B
authors.initials: KA
authors.lastname: Cauthon
mesh_terms: D052160:Benzothiazoles / Q000009:adverse effects*; D018491:Dopamine Agonists / Q000009:adverse effects*; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D000077487:Pramipexole
chemical_list: D052160:Benzothiazoles; D018491:Dopamine Agonists; D007211:Indoles; C046649:ropinirole; D000077487:Pramipexole